Annual report pursuant to Section 13 and 15(d)

Note 14 - Stockholders' Equity (Tables)

v3.22.4
Note 14 - Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
               

Shares Subject to Purchase

 

Exercise Price per Share

   

Expiration Date

   

at December 31, 2022

 
$ 1.90       1/22/2024       6,372  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   

Year ended December 31,

 
   

2022

   

2021

 

Cost of product sales

  $ 104     $ 73  

Research and development cost

    36       77  

General and administrative expense

    2,115       2,051  

Total

  $ 2,255     $ 2,201  
Share-based Payment Arrangement, Option and Restricted Stock Unit, Activity [Table Text Block]
           

Options Outstanding

   

RSUs Outstanding

 
                   

Weighted-

           

Weighted-

 
   

Number of

           

Average

           

Average

 
   

Shares

           

Exercise

           

Grant Date

 
   

Available for

   

Number of

   

Price Per

   

Number of

   

Fair Value

 
   

Grant

   

Shares

   

Share

   

RSUs

   

Per Share

 

Balance at December 31, 2020

    3,398,870       1,387,673     $ 3.89       5,624,166     $ 0.66  

Granted

    (1,803,172 )                 1,803,172       1.63  

Exercised/ Released

          (347,901 )     2.09       (2,121,220 )     0.91  

Forfeited

    72,303       (13,060 )     8.71       (59,243 )     0.83  

Balance at December 31, 2021

    1,668,001       1,026,712     $ 4.44       5,246,875     $ 1.07  

Authorized

    7,000,000                          

Granted

    (3,691,202 )                 3,691,202       0.69  

Exercised/ Released

                      (2,297,130 )     0.90  

Forfeited

    285,455       (32,445 )     5.78       (253,010 )     1.16  

Balance at December 31, 2022

    5,262,254       994,267     $ 4.40       6,387,937     $ 0.91  
           

Weighted-

   

Weighted-

         
           

Average

   

Average

         
           

Exercise

   

Remaining

   

Aggregate

 
           

Price Per

   

Contractual

   

Intrinsic Value

 
   

Shares

   

Share

   

Life (Years)

   

(in thousands)

 

Outstanding

    994,267     $ 4.40       0.40     $  

Vested and exercisable

    994,267     $ 4.40       0.40     $  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
   

Options Outstanding

   

Options Exercisable

 
           

Weighted-

           

Weighted-

 
           

Average

           

Average

 
           

Remaining

           

Remaining

 
           

Contractual

           

Contractual

 
   

Number of

   

Life

   

Number of

   

Life

 

Range of Exercise Prices Per Share

 

Shares

   

(Years)

   

Shares

   

(Years)

 
                                 

$1.60 - $2.79

    106,361       0.86       106,361       0.86  

$2.80 - $4.50

    450,882       0.33       450,882       0.33  

$4.51 - $7.50

    420,000       0.33       420,000       0.33  

$7.51 - $12.55

    8,690       0.45       8,690       0.45  

$12.56 - $24.81

    8,334       0.84       8,334       0.84  
                                 
      994,267       0.40       994,267       0.40  
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
   

Number of Shares

 

Equity Plan

       

Subject to outstanding options and restricted shares

    7,382,204  

Available for future grants

    5,262,254  

Officer and Director Purchase Plan

    237,382  

Warrants

    6,372  
      12,888,212